Leukemia

Latest News

FDA
FDA Approves Revumenib for Relapsed/Refractory KMT2A-Translocated Acute Leukemia

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

Developers are expected to file a supplemental NDA for revumenib in NPM1-mutated AML in the first half of 2025.
Revumenib Elicits Favorable Efficacy in mNPM1 Acute Myeloid Leukemia

November 15th 2024

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.
Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase

November 14th 2024

Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.
Determining the Next Steps Forward With BTK Inhibitors in Relapsed CLL

November 14th 2024

FDA Approves Obecabtagene Autoleucel in B-Cell ALL
FDA Approves Obecabtagene Autoleucel in B-Cell ALL

November 8th 2024

Latest CME Events & Activities